Redeyes’ long-term view of Dignitana continues to be positive. The sales progression has been slow, but this quarter reached our expectations. The cost control was markedly better and highly important until sales start to pick up. The market fundamentals are still positive, with the CPT 1 codes and CMS decision. We have increased our expectations slightly due to the results beat for 2024e. With minor changes, we lower our Base case value to SEK 5.5 (5.7) per share, with a fair value range of SEK 1.8 to 13 (14) per share.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/